Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)
Public ClinicalTrials.gov record NCT06045507. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8527 Once Monthly in Participants at Low-Risk for HIV-1 Infection
Study identification
- NCT ID
- NCT06045507
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 352 participants
Conditions and interventions
Conditions
Interventions
- MK-8527 Drug
- Placebo to MK-8527 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 7, 2023
- Primary completion
- Dec 11, 2024
- Completion
- Feb 11, 2025
- Last update posted
- Jan 6, 2026
2023 – 2025
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Velocity Clinical Research, North Hollywood ( Site 0054) | North Hollywood | California | 91606 | — |
| Bridge HIV- San Francisco Department of Public Health ( Site 0042) | San Francisco | California | 94102 | — |
| Velocity Clinical Research, Hallandale Beach ( Site 0052) | Hallandale | Florida | 33009 | — |
| Community Medical Care Center ( Site 0056) | Immokalee | Florida | 34142 | — |
| Velocity Clinical Research Rockville ( Site 0048) | Rockville | Maryland | 20854 | — |
| Fenway Health ( Site 0043) | Boston | Massachusetts | 02215 | — |
| Albuquerque Clinical Trials, Inc. ( Site 0044) | Albuquerque | New Mexico | 87102 | — |
| University of Pittsburgh Medical Center-Division of Infectious Diseases ( Site 0041) | Pittsburgh | Pennsylvania | 15213 | — |
| Prism Health North Texas, Oak Cliff Health Center ( Site 0045) | Dallas | Texas | 75208 | — |
| Fred Hutchinson Cancer Center - The Seattle HIV Vaccine Trials Unit ( Site 0057) | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06045507, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2026 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06045507 live on ClinicalTrials.gov.